UBS_Equities-US_Thematic_Research_UBS_Private_Market_Monitor Keeping_Up...-115289694_21页_1mb

UBS Private Market Monitor: Keeping Up with Private Capital Healthcare Summary

Key Highlights

1. Recent Private Company Profiles:

   • UBS analyzes recent reports focusing on software, finance, chemicals & packaging, insurance, and healthcare.
   • Topics include AI integration in cybersecurity, payments innovation, and biotechnology.
   • Example: RSA 2025 conference highlights cautious optimism for AI-driven security.

2. IPO Activity:

   • Recent IPO activity is quiet, with only SPAC-related news.
   • Shein is exploring business model changes due to U.S. tariffs, possibly delaying its London IPO.
   • SPACs dominate upcoming IPOs (25 of 61 announced IPOs in Q1 2025 are SPACs), reflecting investor caution amid macro volatility.

3. Funding Rounds:

   • Tech and healthcare are top industries for large funding.
   • AI-focused startups (e.g., Anysphere, Chaos) are active in recent funding rounds.
   • Healthcare verticals (drug discovery, biotech) increasing their presence in top deals.
   • Tech and healthcare account for ~40% of software funding rounds.

4. Market Trends & Investor Behavior:

   • U.S. fintech deal volume is down ~13% YoY, but capital invested in Q2 is projected to increase by 6%.
   • Private equity prioritizes digital transformation, while insurers focus on cost cutting and consolidation.
   • VC demands for AI startups are more flexible (e.g., veto power over acquisitions).

5. CBER Director Appointment:

   • Vinay Prasad's appointment could affect mRNA therapies and accelerated approval pathways for biologics.

6. Upcoming Events:

   • UBS Private Company FinTech Conference (May 15–16, Napa) will cover POS competition, fintech deal integration, and eCommerce payments.
   • Other scheduled ARC and public events focus on energy transition, biotechnology, and healthcare conferences.

Key Data & Insights

• AI Integration: Dominates fintech and healthcare sectors, influencing VC investments.
• Sector Shifts: Healthcare and tech lead in investments despite ongoing economic headwinds.
• Web3 & Digitalization: Identity management and access technology rising (166% venture deal increase).

Disclaimer Notes

• Investments in small/mid-cap biotech carry high risk/reward profiles.
• UBS’s analysis may conflict with investment decisions due to business relationships with covered companies.

For more details, refer to the official UBS report linked in sections 1–10.